This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
49
KB109 is a novel glycan
Self Supportive Care (SSC) Alone
Cullman Clinical Trials
Cullman, Alabama, United States
American Institute of Research
Los Angeles, California, United States
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California, United States
Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)
Time frame: Day 1 to Day 35
Relative abundance of microbial taxa in fecal samples as assessed by shotgun profiling based on shotgun sequencing.
Change from baseline in relative abundance of microbial taxa (operational taxanomic units) in the KB109 + SSC group versus SSC alone
Time frame: Day 1 to Day 35
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Next Phase Research Alliance
Boca Raton, Florida, United States
Advanced Pharma CR, LLC
Miami, Florida, United States
Hope Clinical Trials
Miami, Florida, United States
Kendall South Medical Center, Inc.
Miami, Florida, United States
Quad Clinical Research
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Inquest Research
Baytown, Texas, United States
...and 2 more locations